Extranodal Male Genital Involvement With Diffuse Large B-Cell Lymphoma.

IF 0.7 Q4 HEMATOLOGY
Case Reports in Hematology Pub Date : 2026-05-19 eCollection Date: 2026-01-01 DOI:10.1155/crh/5511675
James J Fradin, Kavanya Feustel, Mehdi Hamadani, Thomas A Giever
{"title":"Extranodal Male Genital Involvement With Diffuse Large B-Cell Lymphoma.","authors":"James J Fradin, Kavanya Feustel, Mehdi Hamadani, Thomas A Giever","doi":"10.1155/crh/5511675","DOIUrl":null,"url":null,"abstract":"<p><p>Primary penile diffuse large B-cell lymphoma (DLBCL) is an exceptionally rare extranodal presentation that can be challenging to diagnose due to its nonspecific symptoms. We report the case of an 84-year-old male who initially presented with phimosis who subsequently developed a nonhealing surgical wound and B symptoms. Imaging and biopsy ultimately revealed Stage IVB activated B-cell type DLBCL. He was treated with dose-reduced rituximab, cyclophosphamide, doxorubicin, prednisone, and polatuzumab vedotin (modified R-mini-CHOP). Despite his advanced disease, he achieved a partial metabolic response with negative minimal residual disease. We also summarize prior reported cases of penile DLBCL, highlighting patterns in disease presentation and treatment approaches. This case emphasizes the importance of maintaining a broad differential for penile lesions to avoid delays in diagnosis and treatment, and it illustrates the integration of novel agents such as polatuzumab vedotin for frail or elderly patients.</p>","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2026 ","pages":"5511675"},"PeriodicalIF":0.7000,"publicationDate":"2026-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13189451/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Hematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/crh/5511675","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Primary penile diffuse large B-cell lymphoma (DLBCL) is an exceptionally rare extranodal presentation that can be challenging to diagnose due to its nonspecific symptoms. We report the case of an 84-year-old male who initially presented with phimosis who subsequently developed a nonhealing surgical wound and B symptoms. Imaging and biopsy ultimately revealed Stage IVB activated B-cell type DLBCL. He was treated with dose-reduced rituximab, cyclophosphamide, doxorubicin, prednisone, and polatuzumab vedotin (modified R-mini-CHOP). Despite his advanced disease, he achieved a partial metabolic response with negative minimal residual disease. We also summarize prior reported cases of penile DLBCL, highlighting patterns in disease presentation and treatment approaches. This case emphasizes the importance of maintaining a broad differential for penile lesions to avoid delays in diagnosis and treatment, and it illustrates the integration of novel agents such as polatuzumab vedotin for frail or elderly patients.

结外男性生殖器浸润弥漫性大b细胞淋巴瘤。
原发性阴茎弥漫性大b细胞淋巴瘤(DLBCL)是一种非常罕见的结外表现,由于其非特异性症状,诊断具有挑战性。我们报告一例84岁男性,最初表现为包茎,后来出现手术伤口不愈合和B症状。影像学和活检最终显示为IVB期活化b细胞型DLBCL。患者接受减剂量利妥昔单抗、环磷酰胺、阿霉素、强的松和polatuzumab vedotin(改良R-mini-CHOP)治疗。尽管他的疾病晚期,他取得了部分代谢反应阴性最小残留疾病。我们还总结了先前报道的阴茎DLBCL病例,突出了疾病表现和治疗方法的模式。本病例强调了对阴茎病变保持广泛鉴别以避免诊断和治疗延误的重要性,并说明了新药物如polatuzumab vedotin对体弱或老年患者的整合。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
51
审稿时长
13 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书